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Abstract
Background
With a cholesterol-lowering focus for diabetic adults and in the age of polypharmacy, it is
important to understand how lipid profile levels differ among those with and without
diabetes.
Objective
Investigate the means, differences, and trends in lipid profile measures [TC, total choles-
terol; LDL-c, low-density lipoprotein; HDL-c, high-density lipoprotein; and TG, triglycerides]
among US adults by diabetes status and cholesterol-lowering medication.
Methods
Population number and proportion of adults aged21 years with diabetes and taking cho-
lesterol-lowering medication were estimated using data on 10,384 participants from
NHANES 2003–2012. Age-standardized means, trends, and differences in lipid profile mea-
sures were estimated by diabetes status and cholesterol medication use. For trends and dif-
ferences, linear regression analysis were used adjusted for age, gender, and race/ethnicity.
Results
Among diabetic adults, 52% were taking cholesterol-lowering medication compared to the
14% taking cholesterol-lowering medication without diabetes. Although diabetic adults had
significantly lower TC and LDL-c levels than non-diabetic adults [% difference (95% confi-
dence interval): TC = -5.2% (-6.8 –-3.5), LDL-c = -8.0% (-10.4 –-5.5)], the percent difference
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was greater among adults taking cholesterol medication [TC = -8.0% (-10.3 –-5.7); LDL-c =
-13.7% (-17.1 –-10.2)] than adults not taking cholesterol medication [TC = -3.5% (-5.2
–-1.6); LDL-c = -4.3% (-7.1 –-1.5)] (interaction p-value: TC = <0.001; LDL-c = <0.001). From
2003–2012, mean TC and HDL-c significantly decreased among diabetic adults taking cho-
lesterol medication [% difference per survey cycle (p-value for linear trend): TC = -2.3%
(0.003) and HDL-c = -2.3% (0.033)]. Mean TC, HDL-c, and LDL-c levels did not significantly
change from 2003 to 2012 in non-diabetic adults taking cholesterol medication or for adults
not taking cholesterol medications.
Conclusions
Diabetic adults were more likely to have lower lipid levels, except for triglyceride levels, than
non-diabetic adults with profound differences when considering cholesterol medication use,
possibly due to the positive effects from clinical diabetes management.
Introduction
In 2012, 29.1 million people in the U.S. had diabetes with 1.7 million new diabetes cases
among people aged20 years (National Diabetes Statistics Report, 2014). Since people with
diabetes have an increased cardiovascular disease (CVD) risk [1, 2], lipid management along
with other risk factors is a particular focus in this population. The 2013 guidelines from the
American College of Cardiology and the American Heart Association (2013 ACC/AHA) and
the 2016 American Diabetes Association Standard of Medical Care in Diabetes (2016 ADA)
provided updated guidance on high blood cholesterol treatment recommendations and the eli-
gibility determination for diabetic adults. If the 2013 ACC/AHA guidelines had been in effect
from 2005 through 2012, 88% of diabetic adults would have been eligible for cholesterol-lower-
ing medication [3]. Current guidelines (2013 ACC/AHA and 2016 ADA) potentially increased
the number who are now eligible for HMG-CoA reductase (statin) therapy [2, 4]. Since eligi-
bility for cholesterol-lowering medication among diabetic adults focuses predominantly on
low-density lipoprotein cholesterol (LDL-c) levels; in the age of polypharmacy, it is important
to understand how lipid profile levels differ among U.S. adults with and without diabetes,
while accounting for cholesterol-lowering medication use.
Lipid levels have consistently been associated with cardiovascular events risk [1, 5–7].
Although LDL-c levels tend not to be higher among diabetic than non-diabetic adults [8], dys-
lipidemia and lipid levels associated with CVD presents differently among diabetic adults [9,
10]. Triglyceride (TG) levels tend to be greater among diabetic adults and studies have found
that TG, as well as non-high-density lipoprotein (non-HDL-c) or total cholesterol (TC)/high-
density lipoprotein (HDL-c) ratio, are better coronary heart disease predictors than LDL-c
when compared to non-diabetic adults [9, 10]. Although cholesterol-lowering medication use
among diabetic adults has demonstrated to lower CVD incidence and all-cause mortality [11],
the most effective strategy for managing diabetic dyslipidemia may require a different treat-
ment regimen than for people eligible for treatment without diabetes [12].
A better understanding of how lipid profile levels differ among diabetic adults while
accounting for cholesterol-lowering medication use is needed to demonstrate the burden and
distribution of diabetic dyslipidemia in the U.S. and to identify potential opportunities for
improvement. Since cholesterol management guidelines have historically emphasized the need
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for medication use among diabetic adults, understanding how lipid profile levels differ may
provide insight on differentiating increased CVD risk in this group. The study objectives were
to examine the trends and differences in lipid profile levels among U.S. adults by diabetes sta-
tus and cholesterol-lowering medication use.
Materials and methods
The National Health and Nutrition Examination Survey (NHANES) assesses the health and
nutritional status of the U.S. population and has been previously described in detail [13].
Briefly, NHANES uses a complex multi-stage probability design to select a sample representa-
tive of the civilian, non-institutionalized U.S. resident. The survey entails a home interview
which collects a variety of information on demographics, socioeconomic, health conditions,
and health-related behaviors followed by a physical examination at a mobile exam center
(MEC). Physical exams consist of medical, dental, and anthropometric measurements. Partici-
pants were randomly assigned to a laboratory session at the MEC to collect blood samples.
Only participants assigned to the morning session were asked to fast at least 9 hours prior to
their appointment. All the measures of plasma fasting glucose (FG), hemoglobin A1c, and
lipid profile levels (TC, LDL-c, HDL-c, non-HDL-c, and TG) were only available for partici-
pants with a morning session. LDL-c was calculated in accordance with the Friedewald equa-
tion [14] using the measured values of TC, TG, and HDL-c. Since the Friedewald equation is
not valid for TG >400 mg/dL, LDL-c was only calculated for TG400 mg/dL. Of the 11,546
participants with a TG measurement, 262 (2%) had TG>400 mg/dL (109 with diabetes and
153 without diabetes). Non-HDL-c was calculated by subtracting HDL-c from TC (TC–HDL-
c). The prescription medication questions were collected during the home interview and
obtained information on medication used during the past 30 days from the date of visit. Inter-
viewers directly recorded drug names from the medication bottles, when available. Examina-
tion response rates for NHANES cycles of 2003 through 2012 ranged from 70–77%. NHANES
protocol has been approved by the National Center for Health Statistics Research Ethics
Review Board. Data used in this study were de-identified and are publicly available at https://
wwwn.cdc.gov/nchs/nhanes/default.aspx.
From NHANES 2003–2012, we included non-pregnant adults aged21 years from the
morning fasting sample who fasted 8 to<24 hours at the time of the MEC visit (n = 10,760).
Participants were excluded if they were missing data on diabetes status or cholesterol-lowering
medication use (n = 27), or laboratory measures (n = 343). The final sample size was 10,390
participants. Fasting morning sample weights were used for all analyses.
Diabetes was defined as: FG 126 mg/dL, hemoglobin A1c 6.5% (48 mmol/mol),
answering yes to the question “Have you ever been told by a doctor or health professional that
you have diabetes or sugar diabetes?”, or reported taking any diabetes medications. Medication
use for diabetes was determined for people with diabetes based on: 1) responding “yes” to
either question, "Are you now taking insulin?" or "Are you now taking diabetic pills to lower
your blood sugar?", or 2) diabetic medications identified in the prescription medication data
files. Prescription diabetic medication classes included nonsulfonylureas, sulfonylureas, insu-
lin, thiazolidinediones, meglitinides, alpha-glucosidase inhibitors, combination medications,
or other.
Cholesterol-lowering medication use was determined based as 1) responding “yes” to both
of the following questions, "To lower your blood cholesterol, have you ever been told by a doc-
tor or other health professional to take prescribed medicine?" and "Are you now following this
advice to take prescribed medicine?" or 2) cholesterol-lowering medications identified in the
prescription medication data files. Prescription cholesterol-lowering medication classes
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considered were HMG-CoA reductase inhibitors (statins) and non-statin cholesterol medica-
tion (bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, combina-
tion medications, or other).
Statistical methods
We estimated the prevalence of adults with and without diabetes overall and by subgroups,
including: gender, age (21–39, 40–64, and65 years), race/ethnicity (Mexican-American,
non-Hispanic white, and non-Hispanic black), body mass index (BMI) [normal (18.5–<25
kg/m2), overweight (25–<30 kg/m2), and obese (30 kg/m2)], poverty-to-income ratio (PIR
<100, 100–299, 300–499, and500%), education among those aged25 years (<high school
diploma, high school diploma, some college, and college degree), any health insurance cover-
age (yes/no), any routine place to go for health care (yes/no), and taking cholesterol-lowering
medication (yes/no). We calculated population estimates using the Current Population Sur-
veys for 2003–2010 and the American Community Survey for 2011–2012, by averaging the
population from the 5 NHANES cycles used in this study: 2003–2004 through 2011–2012. We
estimated age standardized means of lipid profile and glycemic (FG and hemoglobin A1c) lev-
els between those with diabetes and without as well as within subgroups of cholesterol-lower-
ing medication use by the direct method using the U.S. Census 2010 population (age groups
were in 5 year increments starting with age of 20 years: 20–24, 25–29, ect.). We performed lin-
ear regression analyses to test for differences in lipid profile levels (dependent variables)
between those with and without diabetes (independent variable), by cholesterol-lowering med-
ication use. We also tested for the differences in glycemic levels (dependent variables) between
those taking and not taking cholesterol-lowering medication (independent variable), by diabe-
tes status. We tested for interactions between diabetes status and cholesterol-lowering medica-
tion use in association with lipid profile and glycemic levels. We tested for significant linear
trends in lipid profile and glycemic levels over time within subgroups of diabetes status and
cholesterol-lowering medication use. Lipid profile and glycemic levels were log transformed in
the regression analyses to meet the criteria of normally distributed standard errors. Results
were back transformed and represent the percent difference for one unit increase in the inde-
pendent variable (depending on the model either diabetes status, cholesterol medication use,
or survey cycle years). We adjusted all linear regression models for age (years), gender, and
race/ethnicity (Mexican-American, other Hispanic, non-Hispanic white, non-Hispanic black,
and other race/multi-racial). For models with lipid profile levels as dependent variables among
all adults, we also adjusted for cholesterol medication use. For models with glycemic levels as
dependent variables, we made further adjustments for diabetes status in models among all
adults and diabetes medication use for models among diabetic adults. We determined stati-
stically significant results for p-values <0.05. We used STATA version 14.0 to perform all
analyses, accounting for the complex sampling design, using the morning fasting subsample
weights.
Results
From 2003 through 2012, 12.2% or about 26 million of U.S. adults aged21 years had diabetes
(Table 1). Compared to non-diabetic adults, diabetic adults were older (90.5% vs 60.7%
aged 40 years), had greater BMI (62.2% vs 31.3% were obese), had lower PIR (62.0% vs
47.5% with PIR<300%), and lower education attainment (55.6% vs 39.7% with high school
diploma or less) (p-values <0.001). Among diabetic adults, 52.2% were taking cholesterol-low-
ering medication than 14.0% of non-diabetic adults (p-value <0.001).
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Table 1. Characteristics of US adults aged21 years by diabetes statusa—National Health and Nutrition Examination Survey, 2003–2012.
All No Diabetes Diabetes
N = 10390 N = 8620 N = 1770
N
sample
% (95% CI) N population (in
millions)
N
sample
% (95% CI) N population (in
millions)
N
sample
% (95% CI) N population (in
millions)
All 10390 100.0 (100.0,
100.0)
210.5 8616 87.8 (86.9,
88.7)
184.8 1774 12.2 (11.3,
13.1)
25.7
Gender
Men 5113 48.2 (47.3,
49.1)
101.4 4189 47.8 (46.8,
48.7)
88.3 924 51.4 (48.4,
54.4)
13.2
Women 5277 51.8 (50.9,
52.7)
109.0 4427 52.2 (51.3,
53.2)
96.5 850 48.6 (45.6,
51.6)
12.5
Age group (yrs)
21–40 3252 35.7 (33.9,
37.4)
75.1 3119 39.3 (37.4,
41.2)
72.6 133 9.5 (7.9,
11.5)
2.4
40–64 4441 46.6 (45.1,
48.0)
98.1 3621 46.0 (44.4,
47.6)
85.0 820 50.6 (47.3,
53.9)
13.0
> = 65 2697 17.8 (16.8,
18.8)
37.5 1876 14.7 (13.7,
15.7)
27.2 821 39.9 (36.5,
43.4)
10.2
Race/Ethnicityb
Mexican-
American
1773 8.9 (7.3, 10.8) 18.7 1428 8.7 (7.2,
10.5)
16.1 345 10.6 (7.9,
14.0)
2.7
Non-Hispanic
White
4960 78.6 (75.8,
81.2)
165.4 4253 79.6 (77.0,
82.0)
147.1 707 71.4 (66.4,
75.9)
18.3
Non-Hispanic
Black
2050 12.4 (10.7,
14.4)
26.1 1599 11.7 (10.1,
13.5)
21.6 451 18.1 (14.9,
21.8)
4.6
Body mass indexc
Normal 2879 31.0 (29.6,
32.4)
60.7 2639 33.5 (32.1,
34.9)
57.5 240 13.2 (10.9,
15.4)
3.1
Overweight 3495 33.9 (32.6,
35.1)
66.2 3017 35.2 (33.8,
36.6)
60.3 478 24.6 (21.8,
27.3)
5.9
Obese 3720 35.1 (33.7,
36.6)
68.6 2716 31.3 (29.9,
32.8)
53.8 1004 62.2 (58.7,
65.8)
14.9
Poverty-to-income
ratiod
<100% 1860 12.7 (11.6,
13.9)
26.7 1503 12.4 (11.3,
13.7)
22.9 357 14.7 (12.4,
17.3)
3.8
100–299% 4108 36.6 (34.5,
38.7)
77.0 3310 35.1 (33.0,
37.3)
64.9 798 47.3 (43.5,
51.1)
12.1
300–499% 1956 25.6 (23.9,
27.4)
53.9 1684 26.1 (24.4,
28.0)
48.2 272 22.0 (18.6,
25.9)
5.6
> = 500% 1695 25.1 (23.1,
27.2)
52.8 1511 26.3 (24.2,
28.5)
48.6 184 16.0 (13.2,
19.4)
4.1
Education (among those aged 25 yrs or older)e
<High school
diploma
2717 18.4 (16.9,
20.0)
38.7 2045 17.2 (15.6,
18.9)
31.8 672 26.6 (23.8,
29.6)
6.8
High school
diploma
2237 23.4 (22.0,
24.8)
49.3 1790 22.5 (21.1,
24.0)
41.6 447 29.0 (25.9,
32.5)
7.4
Some college 2539 29.0 (27.6,
30.5)
61.0 2140 29.4 (27.8,
31.0)
54.3 399 26.4 (23.3,
29.6)
6.8
> = College
degree
2163 29.2 (26.9,
31.6)
61.5 1921 30.9 (28.5,
33.4)
57.1 242 17.9 (15.2,
21.0)
4.6
Health insurance coveragef
Yes 7988 80.5 (79.1,
81.9)
169.4 6512 79.8 (78.2,
81.2)
147.5 1476 85.8 (83.6,
87.8)
22.0
(Continued)
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Among adults taking cholesterol-lowering medication, the age-standardized LDL-c means
were lower among diabetic adults (99.6 mg/dL) than non-diabetic adults (118.7 mg/dL)
(Wald p-values = 0.0002) (Table 2). Similarly, among those not taking cholesterol-lowering
medication, diabetic adults had lower age-standardized means of TC and LDL-c (194.9 and
116.9 mg/dL, respectively) than non-diabetic adults (200.6 and 120.7 mg/dL, respectively)
(p-values for TC = 0.002 and LDL = 0.021). However, age-standardized mean TG was higher
among diabetic adults taking cholesterol-lowering medication (176.8 mg/dL) than those not
taking cholesterol-lowering medication or non-diabetic adults (ranging from 119.8–146.0
mg/dL). Although age-standardized mean HDL-c among diabetic adults taking cholesterol-
lowering medication (52.2 mg/dL) was not significantly different than non-diabetic adults tak-
ing cholesterol-lowering medication (50.7 mg/dL), it was significantly lower in diabetic adults
not taking cholesterol-lowering medication (48.8 mg/dL) (p-value = 0.0017). Although non-
HDL-c among adults taking cholesterol-lowering medication were not statistically different
between adults with diabetes (135.0 mg/dL) and those without (144.1 mg/dL) (p-value = 0.07),
the non-HDL-c levels were significantly lower for diabetic adults taking cholesterol-lowering
medication (135.0 mg/dL) than diabetic adults not taking medication (146.0 mg/dL) (p-value
<0.001).
Table 1. (Continued)
All No Diabetes Diabetes
N = 10390 N = 8620 N = 1770
N
sample
% (95% CI) N population (in
millions)
N
sample
% (95% CI) N population (in
millions)
N
sample
% (95% CI) N population (in
millions)
No 2402 19.5 (18.1,
20.9)
41.0 2104 20.2 (18.8,
21.8)
37.3 298 14.2 (12.2,
16.4)
3.6
Routine place to go for healthcareg
Yes 8846 86.2 (85.2,
87.1)
181.4 7197 85.1 (84.0,
86.1)
157.3 1649 94.1 (92.2,
95.5)
24.2
No 1544 13.8 (12.9,
14.8)
29.0 1419 14.9 (13.9,
16.0)
27.5 125 5.9 (4.5,
7.8)
1.5
Taking cholesterol lowering medicationh
Yes 2264 18.7 (17.6,
19.8)
39.4 1323 14.0 (13.0,
15.2)
25.9 941 52.2 (49.6,
54.7)
13.4
No 8126 81.3 (80.2,
82.4)
171.1 7293 86.0 (84.8,
87.0)
158.9 833 47.8 (45.3,
50.4)
12.3
P-value <0.05 for all Pearson Chi-square tests, testing difference of each characteristic between adults with and without diabetes.
a Diabetes defined as: fasting glucose126 mg/dL, hemoglobin A1c6.5, responded yes to the question "Other than pregnancy, have you ever been told by a doctor
that you have diabetes?", or taking medication for diabetes.
b When stratifying results by race/ethnicity, 1607 participants identified as other Hispanic, non-Hispanic Asian, and other race/multi-racial were not included due to
small numbers. However, they are include in all other analyses.
c The body mass index stratification does not include the 296 underweight participants.
d Ratio of family income to poverty as defined by the US Census Bureau. Information available at http://www.census.gov/hhes/www/poverty/methods/definitions.
html#ratio of income to poverty. For 771 participants, information on ratio of family income to poverty was missing.
e Of the 734 participants not included in the education stratified estimates, 5 refused to answer the question, 9 did not know the highest level of school completed, and
the remainder were 21–24 years old and not included.
f Participants were asked, "Are you covered by health insurance or some other health-care plan?"
g Based on the response to the question, "Is there a place that you usually go when sick or need advice about health?"
h Based on 1) responding “yes” to both of the following questions, "To lower your blood cholesterol, have you ever been told by a doctor or other health professional to
take prescribed medicine?" and "Are you now following this advice to take prescribed medicine?" or 2) cholesterol lowering medication was identified in the prescription
medication questionnaire.
https://doi.org/10.1371/journal.pone.0193756.t001
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There were significant interactions (p-values range: 0.010–<0.001) between diabetes status
and cholesterol-lowering medication use in association with TC, LDL-c, TG, and non-HDL-c
levels (Table 3). On average, TC, LDL-c, HDL-c, and non-HDL-c levels were lower among
diabetic adults than non-diabetic adults [% difference (95% confidence interval) = -5.2% (-6.8,
-3.5), -8.0% (-10.4, -5.5), -11.5% (-13.1, -9.9), and -2.7% (-5.0, -0.4), respectively]. However,
TG levels on average were greater for diabetic adults than non-diabetic adults [19.5% (14.8,
24.4)]. For adults taking cholesterol-lowering medication than those not, the percent differ-
ence between those with diabetes and those without were greater for TC (-8.0% vs -3.5%), LDL
(-13.7% vs -4.3%), and non-HDL-c (-7.2% vs 0.2%) and smaller for TG (15.8% vs 23%).
The interaction between diabetes status and cholesterol-lowering medication use in associa-
tion with glycemic levels was only significant for FG (interaction p-value = 0.040) (Table 3).
FG and hemoglobin A1c levels, on average, were higher among adults taking cholesterol-low-
ering medication than those not taking cholesterol-lowering medication [1.7% (0.6, 2.8) and
2.3% (1.6, 3.1), respectively]. For FG, the percent difference between adults taking cholesterol-
lowering medication and those not taking cholesterol-lowering medication was greater among
non-diabetic adults than among diabetic adults [1.8% (1.1, 2.6) vs 0.4% (-4.0, 4.9)].
For diabetic adults taking cholesterol-lowering medication, there was an average decline in
levels of TC [% difference per survey cycle = -2.3% (-3.7, -0.8)], HDL-c [-2.3% (-4.2, -0.2)], and
non-HDL-c [-2.3% (-4.2, -0.3)] from 2003–2012 (Table 4). There were no significant changes
Table 2. Age standardizeda means of lipid profile levels and fasting glucose among US adults aged21 years by diabetesb and cholesterol medication usec—
National Health and Nutrition Examination Survey, 2003–2012.
Diabetes No Diabetes
All Taking cholesterol
medication
Not taking cholesterol
medication
All Taking cholesterol
medication
Not taking cholesterol
medication
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
Total Cholesterol(mg/
dL)d,e
187.0
(183.35,190.57)
187.2 (183.28,191.21) 194.9 (191.32,198.44) 197.0
(195.88,198.22)
194.8 (187.00,202.68) 200.6 (199.31,201.96)
LDL-cholesterol (mg/
dL)d,e,f
108.0
(105.10,110.86)
99.6 (95.47,103.81) 116.9 (113.57,120.15) 117.4
(116.42,118.48)
118.7 (109.52,127.92) 120.7 (119.55,121.87)
Triglyceride (mg/
dL)d,e,f,g
151.0
(142.53,159.43)
176.8 (162.90,190.78) 146.0 (138.63,153.33) 121.3
(119.36,123.18)
127.3 (120.25,134.32) 119.8 (117.70,121.95)
HDL-Cholesterol (mg/
dL)d,e,g
48.8 (47.27,50.33) 52.2 (51.06,53.34) 48.8 (47.09,50.58) 55.3 (54.86,55.83) 50.7 (49.20,52.18) 56.0 (55.42,56.50)
Non-HDL-cholesterol
(mg/dL)e
138.2 (134.53,
141.79)
135.0 (130.82, 139.26) 146.0 (142.18, 149.91) 141.7 (140.50,
142.91)
144.1 (135.40, 152.90) 144.7 (143.33, 146.02)
Fasting Glucose (mg/
dL)d,f,g
152.3
(143.98,160.52)
149.4 (141.80,156.97) 154.4 (147.32,161.40) 97.9 (97.57,98.32) 101.0 (100.07,101.85) 97.6 (97.25,98.02)
Hemoglobin A1c
(%)d,e,f,g
7.2 (6.98,7.45) 7.9 (7.65,8.05) 7.2 (6.92,7.39) 5.4 (5.35,5.38) 5.5 (5.43,5.54) 5.3 (5.34,5.36)
a Means were age standardized to the U.S. Census 2010 population.
b Diabetes defined as: fasting glucose126 mg/dL, hemoglobin A1c6.5, responded yes to the question "Other than pregnancy, have you ever been told by a doctor
that you have diabetes?", or taking medication for diabetes.
c Based on 1) responding “yes” to both of the following questions, "To lower your blood cholesterol, have you ever been told by a doctor or other health professional to
take prescribed medicine?" and "Are you now following this advice to take prescribed medicine?" or 2) cholesterol lowering medication was identified in the prescription
medication questionnaire.
d P-value <0.05 for mean difference test in adults not taking cholesterol medication between those with diabetes and those without.
e P-value <0.05 for mean difference test in adults with diabetes between those taking and not taking cholesterol medication.
f P-value <0.05 for mean difference test in adults taking cholesterol medication between those with diabetes and those without.
g P-value <0.05 for mean difference test in adults without diabetes between those taking and not taking cholesterol medication.
https://doi.org/10.1371/journal.pone.0193756.t002
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in mean lipid profile or glycemic levels for diabetic adults not taking cholesterol-lowering
medication from 2003–2012. Among non-diabetic adults, average levels of TG declined from
2003 through 2012 for those taking [-5.0% (-7.3, -2.7)] and not taking [-1.9% (-3.1, -0.7)] cho-
lesterol-lowering medication; while hemoglobin A1c increased in those taking [0.4% (<0.1,
0.8)] and not taking [0.5% (0.4, 0.7)] cholesterol-lowering medication.
Discussion
One in eight U.S. adults aged21 years had diabetes during 2003–2012. Despite historical
cholesterol management guidelines focusing on cholesterol-lowering medication use among
people with diabetes, only 52% of diabetic adults were taking cholesterol-lowering medication.
However, efforts to better adhere to these guidelines were noted with the increase in choles-
terol-lowering medication use among adult with diabetes during 2003 to 2012 [44% in 2003–
2004 to 52% in 2011–2012 (p-value = 0.01)], whereas cholesterol-lowering medication use in
non-diabetic adults did not significantly change during this time (12% to 16%, p-value = 0.19)
Table 3. Percent difference in lipid profiles among those with and without diabetesa and by cholesterol medication useb and percent difference in glycemic levels
among those taking and not taking cholesterol medicationb by diabetes statusa—National Health and Nutrition Examination Survey, 2003–2012.
Percent difference between those with and without diabetesc
All adults Taking cholesterol medication Not taking cholesterol medication P-value (interaction)e
% Differenced (95% CI) P-value % Differenced (95% CI) P-value % Differenced (95% CI) P-value
Total Cholesterol -5.2 (-6.8, -3.5) <0.001 -8.0 (-10.3, -5.7) <0.001 -3.5 (-5.2, -1.6) <0.001 <0.001
LDL-c -8.0 (-10.4, -5.5) <0.001 -13.7 (-17.1, -10.2) <0.001 -4.3 (-7.1, -1.5) 0.004 <0.001
Triglycerides 19.5 (14.8, 24.4) <0.001 15.8 (10.1, 21.9) <0.001 23.0 (16.6, 29.6) <0.001 0.010
HDL-c -11.5 (-13.1, -9.9) <0.001 -10.2 (-12.7, -7.6) <0.001 -12.8 (-14.9, -10.7) <0.001 0.051
Non-HDL-c -2.7 (-5.0, -0.4) 0.027 -7.2 (-10.1, -4.2) <0.001 0.2 (-2.6, 3.1) 0.885 <0.001
Percent difference between those taking and not taking cholesterol medicationf
All adults No Diabetes Diabetes P-value (interaction)h
% Differenceg
(95% CI)
P-value % Differenceg (95% CI) P-value % Differenceg (95% CI) P-value
Fasting glucose 1.7 (0.6, 2.8) 0.004 1.8 (1.1, 2.6) <0.001 0.4 (-4.0, 4.9) 0.870 0.040
Hemoglobin A1c 2.3 (1.6, 3.1) <0.001 1.9 (1.4, 2.5) <0.001 0.8 (-1.8, 3.5) 0.550 0.261
a Diabetes defined as: fasting glucose126 mg/dL, hemoglobin A1c6.5, responded yes to the question "Other than pregnancy, have you ever been told by a doctor
that you have diabetes?", or taking medication for diabetes.
b Based on 1) responding “yes” to both of the following questions, "To lower your blood cholesterol, have you ever been told by a doctor or other health professional to
take prescribed medicine?" and "Are you now following this advice to take prescribed medicine?" or 2) cholesterol lowering medication was identified in the prescription
medication questionnaire based on prescription bottles.
c Percent difference [% mg/dL difference in the dependent variable (lipid profile measures) between those without diabetes to those with diabetes] were estimated using
linear regression and adjusting for age, gender, and race/ethnicity. For models among all adults, cholesterol medication use was also included in the model.
d Since lipid profile levels were log transformed as dependent variables in the linear regression models, coefficients were back transformed and represent average
percent difference in levels between those with and without diabetes.
e P-value testing for interaction between diabetes status and cholesterol lowering medication use in association with lipid profile levels adjusted for age, gender, and
race/ethnicity.
f Percent difference in glycemic levels [% difference in the dependent variable (glycemic measures) between those not taking cholesterol medications to those taking
cholesterol medication] were estimated using linear regression and adjusting for age, gender, and race/ethnicity. For model among all adults, adjusted for age, gender,
race/ethnicity, and diabetes status. For models among those with diabetes, adjusted for age, gender, race/ethnicity, and diabetes medication use.
g Since glycemic levels were log transformed as dependent variables in the linear regression models, coefficients were back transformed and represent average percent
difference in glycemic measure between those taking and not taking cholesterol medication.
h P-value testing for interaction between diabetes status and cholesterol lowering medication use in association with glycemic levels adjusted for age, gender, and race/
ethnicity.
https://doi.org/10.1371/journal.pone.0193756.t003
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(data not shown). Mean TC, LDL-c, and HDL-c levels were significantly lower among diabetic
adults than non-diabetic adults regardless of cholesterol-lowering medication use. In fact, a
significant interaction was observed between diabetes status and cholesterol-lowering medica-
tion use with mean TC, LDL-c, TG, and non-HDL-c levels, implying that U.S. diabetic adults
taking cholesterol-lowering medication have better management of their TC, LDL-c, and
non-HDL-c levels, but worse control of TG levels, than non-diabetic adults taking cholesterol-
lowering medication. Although mean TC, LDL-c, HDL-c, and non-HDL-c levels did not
change from 2003 to 2012 for U.S. non-diabetic adults or those not taking cholesterol-lowering
medication; there was a significant decline in mean TC levels for U.S. diabetic adults taking
cholesterol-lowering medication which could be due to the increase in cholesterol-lowering
medication use, medication dosage, or better medication adherence among diabetic adults
during this time.
Even though diabetic adults had lower TC, LDL-c, and non-HDL-c levels than non-diabetic
adults, they had significantly greater TG and lower HDL-c levels. Furthermore, diabetic adults
taking cholesterol-lowering medication had mean TG levels near 177 mg/dL compared with
146 mg/dL among diabetic adults not taking cholesterol-lowering medication. Although this
was a cross-sectional study, it is possible that diabetic adults taking cholesterol-lowering medi-
cation may have additional comorbidities partially explaining the higher TG levels, such as
hypertension, than those not on medication. In this study, 45% of diabetic adults taking cho-
lesterol-lowering medication had hypertension than the 25% of diabetic adults not taking cho-
lesterol-lowering medication, implying that those taking the cholesterol-lowering medication
have a greater CVD risk than those not on the medication. Despite the potential increased
CVD risk among diabetic adults taking cholesterol-lowering medication due to greater TG lev-
els and more hypertension, those adults did have lower TC and LDL levels than diabetic adults
not taking cholesterol-lowering medication. Since studies have found that TG levels as well as
non-HDL-c may be better predictors of CVD risk and all-cause mortality than LDL-c among
adults with type 2 diabetes [9, 10, 15, 16], consideration of TG management is necessary when
Table 4. Linear trends over timea in lipid profile and glycemic levels among US adults aged21 years by diabetesb and cholesterol medication usec—National
Health and Nutrition Examination Survey, 2003–2012.
Diabetes and taking cholesterol
medication
Diabetes and not taking
cholesterol medication
No Diabetes and taking
cholesterol medication
No Diabetes and not taking
cholesterol medication
% Differenced (95% CI) P-value % Differenced (95% CI) P-value % Differenced (95% CI) P-value % Differenced (95% CI) P-value
Total Cholesterol -2.3 (-3.7, -0.8) 0.003 -0.6 (-1.8, 0.5) 0.278 -0.7 (-2.0, 0.6) 0.287 -0.3 (-0.7, 0.2) 0.233
LDL-c -1.8 (-3.8, 0.2) 0.082 0.0 (-2.0, 2.0) 0.963 -0.3 (-2.6, 2.0) 0.773 0.4 (-0.3, 1.0) 0.254
Triglycerides -3.4 (-7.1, 0.5) 0.088 -2.8 (-5.8, 0.2) 0.072 -5.0 (-7.3, -2.7) <0.001 -1.9 (-3.1, -0.7) 0.003
HDL-c -2.3 (-4.2, -0.2) 0.033 -1.0 (-2.3, 0.3) 0.120 0.8 (-0.4, 2.1) 0.199 -0.5 (-1.2, 0.2) 0.155
Non-HDL-c -2.3 (-4.2, -0.3) 0.022 -0.6 (-2.2, 1.0) 0.448 -1.3 (-3.0, 0.5) 0.168 0.0 (-0.6, 0.6) 0.912
Fasting Glucose 0.5 (-2.3, 3.3) 0.747 0.0 (-2.0, 2.1) 0.994 -0.2 (-0.7, 0.3) 0.422 0.2 (-0.1, 0.5) 0.225
Hemoglobin A1c 0.4 (-0.9, 1.7) 0.535 1.1 (-0.4, 2.5) 0.148 0.4 (<0.1, 0.8) 0.032 0.5 (0.4, 0.7) <0.001
a Trends in lipid profiles and fasting glucose were estimated using linear regression and adjusting for age, gender, and race/ethnicity. Models for those with diabetes also
adjusted for diabetes medication.
b Diabetes defined as: fasting glucose126 mg/dL, hemoglobin A1c6.5, responded yes to the question "Other than pregnancy, have you ever been told by a doctor
that you have diabetes?", or taking medication for diabetes.
c Based on 1) responding “yes” to both of the following questions, "To lower your blood cholesterol, have you ever been told by a doctor or other health professional to
take prescribed medicine?" and "Are you now following this advice to take prescribed medicine?" or 2) cholesterol lowering medication was identified in the prescription
medication questionnaire.
d Average percent difference in lipid profile and glycemic levels for every two-year survey cycle (2003–2004, 2005–2006, 2007–2008, 2009–2010, and 2011–2012).
https://doi.org/10.1371/journal.pone.0193756.t004
Lipid profile trends and differences by diabetes status and cholesterol-lowering medication use
PLOS ONE | https://doi.org/10.1371/journal.pone.0193756 March 6, 2018 9 / 13
treating diabetic dyslipidemia and potentially considering combination therapy rather than
statins alone [12, 17, 18] in addition to glycemic control and intensive lifestyle changes.
Although we expected to find mean TC and LDL-c levels to be lower among adults taking
cholesterol-lowering medication than those not [% difference (adjusted for age, gender, race/
ethnicity, and diabetes): TC = -12.8%, p-value<0.001; LDL-c = -23.0% (p-value<0.001)], we
did not expect that among adults not taking cholesterol-lowering medication, the mean TC
and LDL-c levels were greater for non-diabetic adults than diabetic adults. We also anticipated
lipid profile levels among those taking cholesterol-lowering medication to be similar regardless
of diabetes status, not significantly lower among diabetic adults than non-diabetic adults. One
reason could be that diabetic adults are more likely to be on a higher intensity medication or
diabetic adults may be more adherent to their medications than non-diabetic adults, data not
available in NHANES. It is also possible that diabetic adults on average may change their life-
style, including changes in diet and amount of physical activity, to help manage their condition
as a result of national efforts such as the National Diabetes Education Program [19] and there-
fore have better management of their TC and LDL-c levels.
From 2003–2012, there were no linear differences in mean TC, LDL-c, or HDL-c levels for
non-diabetic adults or for those not taking any cholesterol-lowering medication. However, TC,
HDL-c, and non-HDL-c levels significantly decreased during this time for diabetic adults taking
cholesterol-lowering medication. The declining trends in TC and LDL-c among diabetic adults
has been previously documented and believed to be a result of increased uptake of cholesterol-
lowering medication use in this population [20], improvements in clinical management of dia-
betes [21], and an increase in individual diabetes management [22, 23]. Additionally, a decline
in diabetes-related complications including myocardial infarction and stroke was noted [24].
Although there were no significant linear changes in TG levels from 2003–2012 among diabetic
adults, a decrease was seen for non-diabetic adults with a greater decline for non-diabetic adults
taking cholesterol-lowering medication than non-diabetic adults not taking the medication.
Regardless of the decline in TC levels among diabetic adults taking cholesterol-lowering medi-
cation, the decline in HDL-c and no change in TG levels may suggest a more comprehensive
approach that focuses on all lipid profile levels when managing diabetic dyslipidemia.
This study has limitations. First, since information on medication dosage and medication
adherence/persistence were not obtained in NHANES, we were not able to control for the con-
founding effect of dosage and adherence/persistence in our analyses. Therefore, our estimates
may be subject to residual confounding especially if there is differential prescription dosage by
diabetes status or for new users who have not had sufficient time to demonstrate lipid profiles
reflecting the effects of the medication. If diabetic adults have been prescribed higher dosage
medication because of their increased risk than non-diabetic adults, this could result in lower
lipid values among diabetic adults than non-diabetic adults. Second, since NHANES is a cross-
sectional survey, interpretation of the interaction between diabetes status and cholesterol-low-
ering medication use associated with lipid profile levels should be considered with caution.
The differential effectiveness of cholesterol-lowering medication cannot be determined
through this study design. Third, another limitation due to the cross-sectional design is that
pre-medication lipid profile levels were not available and severity of dyslipidemia when medi-
cation began cannot be determined. It is possible that non-diabetic adults may have a more
severe condition since treatment eligibility guidelines have had lower cut-points for diabetic
adults and controlling or looking into this potential explanation was not possible in this study.
Fourth, a potential Age-Period-Cohort effect can be one reason for these findings. The adults
with diabetes are an older group compared to adults without diabetes and experiences along
with exposures including timing of diabetes onset and changes in treatments may explain
some of our findings.
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Future studies are needed to better understand the differences in cholesterol management
and dyslipidemia association with CVD risk in diabetic adults than non-diabetic adults. It is
possible that the etiology between lipid profile levels leading to CVD events may differ for dia-
betic adults than non-diabetic adults. Additionally, it is possible that diabetic adults may
achieve more rapid control of their cholesterol condition than non-diabetic adults due to the
many lifestyle modification resources available to better manage their sugar levels. Although
current guidelines focus on LDL-c levels in determining cholesterol-lowering medication eligi-
bility, the use of cholesterol-lowering medications, particularly statins, will most likely con-
tinue to increase among diabetic adults. The ACC/AHA cholesterol management guidelines
emphasize the importance of lifestyle modifications, the foundation for diabetes management
that may have contributed to the changes and differences in lipid levels among diabetic adults
observed in this study. Expanding the framework from established diabetes management pro-
grams to address other chronic conditions, such as dyslipidemia or hypertension, may have
the potential to also improve those conditions.
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